Moreover, we and others have recently described the enrichment of a myeloid cell population in the circulation of advanced stage cancer patients that co-expresses markers of monocytes/TAMs (such as CD14, CD163) and cDC2s (CD1c)23–25. This evidence concerns the gene CD1C and cancer.